prognosis and outcome of patients with advanced et and pv
Published 10 years ago • 271 plays • Length 20:50Download video MP4
Download video MP3
Similar videos
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
19:03
assessment of novel treatment options for patients with pv
-
18:50
jak inhibitors for et and pv: what have we learned so far?
-
19:04
my view on current and future use of jak inhibitors for et, pv, and mf
-
9:19
debate: should jak inhibitors use be limited to hydroxyurea-resistant/intolerant pv patients? - no
-
1:00:46
ask an mpn expert: tracking and living with mpns
-
4:59
behind the mystery, polycythemia vera
-
8:14
chronic blood cancer at 30 | essential thrombocytosis | mpn
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
23:38
why mpns transform to aml
-
29:27
my view on current and future use of jak inhibitors for et, pv, and mf
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
16:28
update on long-acting interferons for mpn
-
18:36
diagnostic challenges in mpn
-
21:26
the who updated diagnostic criteria for et, pv & mf
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
21:43
hydroxyurea intolerance/resistance in polycythemia vera
-
29:02
current understanding of a genetic/epigenetic basis of classic mpns
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
24:52
combination therapy with jak2 inhibitors in mpn
-
23:39
expert perspectives: jak inhibitors for polycythemia vera
-
21:12
cytokines, cells and inflammation in mpn